OWC Pharmaceutical Research Corp. (OTC: OWCP), a medical cannabis research and consulting company, recently announced that it signed a collaboration agreement with Sheba Academic Medical Center. As the largest hospital in Israel and in the Middle East, Sheba Academic Medical Center is an ideal partner for the company’s medical cannabis research efforts.
“We are very pleased to be working with a highly regarded academic-based medical facility, and in compliance with international regulatory protocols,” said OWC Pharmaceutical Research Corp. CEO Ziv Turner. “This collaboration supports the company’s goal to be in the forefront of research and development of cannabis-based treatments for diseases and medical conditions.”
Chief Science Officer Dr. Alan Shackelford will oversee an initial study conducted by Sheba Academic Medical Center’s Dr. Merav Leiba to explore the effect of several combinations of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) on multiple myeloma. As the second most common hematologic cancer, multiple myeloma represents a market that’s in desperate need of better treatment options.
After receiving approval from the Sheba Academic Medical Center’s Internal Review Board (“IRB”), the company plans on proceeding with the knowledge that the clinical trial does not contradict the principles of the Helsinki Declaration, the Israeli Public Health Regulations, and the Israeli Medical Trials on Human Procedures. The approval could also make future clinical trials easier to initiate.
Shares of OWC Pharmaceutical Research Corp. were trading even in early hours on Wednesday, March 11, 2015 following the news release.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.